Clinical stage Swiss-based biopharmaceutical company focused on neurodegenerative diseases
AC Immune has raised €77M across 3 funding rounds, most recently a Series D+ round in May 2016. Based in Lausanne, Switzerland; founded 2003; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2016-05-01 | Series D+ | €40M | — | View deal → |
| 2014-01-01 | Series D+ | €18M | — | View deal → |
| 2005-05-01 | Series B | €19M | — | View deal → |
